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Summary Advanced biliary tract cancers (ABTC) are
among the deadliest malignancies with limited treatment op-
tions after progression on standard-of-care chemotherapy,
which includes gemcitabine (GEM) and oxaliplatin (OX).
The epidermal growth factor receptor inhibitor erlotinib has
been explored in ABTC with modest efficacy. Erlotinib given
continuously may antagonize the action of chemotherapy
against cycling tumor cells, but pulsatile dosing of erlotinib
with chemotherapy may improve efficacy. The purpose of this
study was to assess the safety of pulsatile erlotinib with
GEMOX. This was a single-institution phase Ib study that
enrolled adult patients with unresectable or metastatic biliary
tract, pancreas, duodenal, or ampullary carcinomas that have
not received any prior treatment for their disease. Dose esca-
lation followed a standard 3 + 3 design, and dose-limiting
toxicities (DLTs) were any treatment-related, first course
non-hematologic grade ≥ 3 toxicity, except nausea/vomiting,
or grade 4 hematologic toxicity. A dose expansion cohort in
ABTC was treated at the MTD. Twenty-eight patients were
enrolled and 4 dose levels were explored. The MTD was er-
lotinib 150 mg + GEM 800 mg/m2 + OX 85 mg/m2. DLTs
were diarrhea and anemia. Most frequent toxicities were nau-
sea (78 %), fatigue (71 %), neuropathy (68 %), and diarrhea
(61 %), predominantly grade 1–2. In the ABTC patients, the
objective response and disease control rates were 29 % and
94 %, respectively, and median overall survival was
18 months. Erlotinib plus GEMOX was well tolerated.
Encouraging anti-tumor activity was seen as evidenced by a
high disease control rate and longer median OS than standard
chemotherapy in the patients with ABTC.
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Introduction
Approximately 7500 new cases of advanced biliary tract can-
cer (ABTC) will be diagnosed each year in the United States
[1]. These are generally divided into intrahepatic cholangio-
carcinoma, extrahepatic cholangiocarcinoma, and cancer of
the gallbladder. In addition, ampulla of Vater cancer is vari-
ably included with biliary cancers. These cancers frequently
present in a stage too advanced for surgical resection, and a
majority of the patients with operable disease will have recur-
rence after complete resection. Several chemotherapy agents
have been evaluated in biliary tract cancer patients, with a
gemcitabine backbone emerging as a standard [2]. A phase
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II trial of single-agent gemcitabine observed an objective re-
sponse rate of 22 % and a disease control rate of 50 % [3]. In a
phase II study of first-line therapy, the combination of
gemcitabine and oxaliplatin (GEMOX) was well tolerated
and resulted in an objective response rate of 35 % and stable
disease in 26 % [4]. Despite the modest success with
gemcitabine combinations, biliary cancers remain among the
deadliest malignancies [5, 6]. Therefore, the development of
new therapeutic regimens to improve treatment efficacy in this
patient population is warranted.
The epidermal growth factor receptor (EGFR) is part of a
complex series of cellular signaling pathways that lead to in-
creased cell proliferation, motility, survival, and angiogenesis,
all of which can lead to tumor growth and progression [7].
EGFR expression is increased in a majority of bile duct can-
cers along with one of its ligands, TGF-alpha [8].
Additionally, HER2, which can dimerize with EGFR thus
activating downstream signaling pathways, is overexpressed
(immunohistochemical staining ≥2) in 15–43 % of biliary
cancers [9–11]. Thus, there has been hope for the development
of EGFR-directed therapies for the treatment of ABTC
[12–14]. Erlotinib, an orally active tyrosine kinase inhibitor
(TKI) of EGFR, is currently FDA approved for use in non-
small cell lung cancer, as well as in pancreatic cancer when
administered in combination with gemcitabine. In a study of
42 patients with either unresectable or metastatic biliary can-
cer being treated with daily oral doses of erlotinib, 7 %
achieved an overall confirmed response, 43 % achieved stable
disease, and the median OS was 7.5 months [14].
Preclinical data from mouse xenograft models suggested
that pulsed gefitinib (another EGFR TKI) before paclitaxel
caused significantly more tumor regression than continuous
gefitinib dosing in combination with paclitaxel [15]. When
pancreas, gastric, and colon cancer cell lines were treated with
combinations of gemcitabine with flavopiridol, an agent that
induces G1/S cell cycle arrest, maximal antitumor effect was
observed with the combination of gemcitabine followed by
flavopiridol, whereas the reverse sequence showed no synergy
[16]. As erlotinib also induces G1/S arrest, we hypothesized
that erlotinib may exhibit sequence-specific synergy with
gemcitabine in a similar manner, such that pulsatile dosing
after chemotherapy with adequate washout prior to repeat
dosing would achieve improved efficacy. Therefore, our pri-
mary objective in this phase Ib study was to determine the
maximum tolerated dose (MTD) and recommended phase II
dose (RP2D) of pulsatile erlotinib in combination with
GEMOX. A secondary objective was to describe any anti-
tumor activity associated with treatment in patients with
ABTC. Exploratory objectives included an investigation of
the relationship between clinical response and the expression
levels of the cytoskeleton protein vimentin and the cell-cell
adhesion protein E-cadherin. Furthermore, given the evidence
that patients with KRAS mutations have a poorer response to
EGFR-directed therapies [17, 18] and that biliary tract cancers
have a spectrum of mutations in EGFR and its downstream
signaling pathways, including KRAS and PIK3CA [19–23],
we evaluated the potential relationship between mutational
status and clinical outcome.
Materials and methods
Ethics statement
This trial was conducted in accordance with Good Clinical
Practice and the Declaration of Helsinki. The study protocol
and informed consent document were approved by our
Institutional Review Board. The study was registered through
ClinicalTrials.gov (NCT00987766).
Study design and patient selection
This single-institution, open-label, phase Ib study of GEMOX
with erlotinib was conducted in patients with previously un-
treated advanced adenocarcinoma of the biliary tract, pancre-
as, duodenum, or ampulla using a standard 3 + 3 design. The
primary objective was to determine the MTD and RP2D of
pulsatile erlotinib in combination with GEMOX. Secondary
objectives were to describe any anti-tumor activity associated
with treatment and to correlate response with tumor cell ex-
pression of E-cadherin and vimentin, and KRAS and EGFR
mutational status. An expanded cohort (n = 10) of patients
with ABTC treated at the MTD was included to further de-
scribe anti-tumor activity.
Adult patients with unresectable or metastatic cancers that
were histologically or cytologically confirmed to be biliary
tract, pancreas, duodenal, or ampullary carcinomas were in-
cluded. Patients must not have had prior chemotherapy or
prior EGFR-targeted therapy for their disease. Patients were
required to have an Eastern Cooperative Oncology Group
performance status (ECOG PS) of 0, 1, or 2 with adequate
bone marrow, renal, and hepatic function defined as pretreat-
ment bilirubin less than 2.5 times the upper limit of normal
(ULN) and hepatic transaminases less than 2.5 times ULN or
less than 5 times ULN if liver metastases were present.
Patients with central nervous system metastases or other re-
cent cancers were excluded. Additionally, patients with un-
controlled infection, significant neuropathy, or any other con-
current medical condition that would make the patient an in-
appropriate candidate for study enrollment were not included.
Treatment
The dose escalation schema (Table 1) began with gemcitabine
(800 mg/m2) as a 10 mg/m2/min infusion on day 1, followed
by oxaliplatin (85 mg/m2) as a 2 h infusion on day 2 every two
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weeks. A fixed dose rate (FDR) of 10 mg/m2/min for
gemcitabine was chosen based on the prior phase II study of
GEMOX in ABTC [4]. The FDR for gemcitabine was used
for all dose levels. The starting dose for erlotinib was 50 mg
given orally once daily for 5 days on days 3–8. Dose escala-
tion was planned for groups of 3 patients until the MTD was
established in a standard 3 + 3 design. No intrapatient dose
escalation was allowed.
The dose limiting toxicity (DLT) was defined as any
treatment-related toxicity occurring in the first two 14-day cy-
cles that was Grade ≥ 3 except for nausea/vomiting or hema-
tologic toxicity. For hematologic toxicity, grade 4 anemia was
a DLT. Grade 4 neutropenia lasting for more than five days or
grade 4 neutropenia of any duration associated with a fever
≥38.5 °C or infection was considered a DLT. Grade 4 throm-
bocytopenia was also dose limiting. For patients with grade 3
or 4 nausea or vomiting not amenable to maximal antiemetic
therapy, the dose level could be reduced 1 or 2 levels at the
discretion of the investigator. Treatment on hold due to toxic-
ity for longer than three weeks was also considered a DLT.
The MTD was said to be exceeded when at least 2 of 6
patients experienced a DLT. MTD is therefore the dose at
which 0 or 1 of 6 experience a DLTwith the next higher dose
level provoking a DLT in 2 of 6 or 2 of 3 patients. Once the
DLT was reached, a cohort of 10 additional patients with




Toxicity assessments were performed each cycle and graded
according to the NCI Common Toxicity Criteria, Version 3.0
(CTCAE v3). All patients who received any chemotherapy on
this study were considered evaluable for safety. Patients
removed from the study during the first four weeks of treat-
ment for reasons other than progressive disease or drug-
related adverse events were considered not evaluable for
DLT and were replaced.
Anti-tumor activity
All eligible patients who received at least two 14-day cycles of
therapy on this study were evaluable for anti-tumor activity.
Patients removed from study before four weeks for progres-
sive disease or drug related adverse event were also evaluable
for efficacy. Tumor evaluation by radiographic examination
was performed every 8 weeks, using Response Evaluation
Criteria in Solid Tumors (RECIST 1.0). Reassessment of the
extent of tumor was done by the same imaging method used to
establish baseline tumor measurements.
Laboratory correlates
A lung triplex sizing assay was performed on pre-treatment
archived tumor specimens (if available) to assess the presence
of EGFR and HER2 exon 20 insertions and EGFR exon 19
deletion [24]. Additionally, the sequences of KRAS exons 2
and 3 and EGFR exons 20 and 21 were evaluated for hotspot
mutations using PCR and Sanger sequencing. Lastly, immu-
nohistochemical (IHC) staining for E-cadherin and vimentin
was performed. A detailed description of the methods for each
correlate analysis can be found in the supplemental methods
section.
Statistical analysis
Patient characteristics were summarized using descriptive sta-
tistics including frequencies and medians. Safety and efficacy
data were summarized for all patients enrolled onto the study,
and for only those patients with ABTC. The objective
Table 1 Dose escalation schema
Dose Level Erlotinib Gemcitabline Oxaliplatin Course 1 (two 14-day cycles) toxicity
0 50 mg 800 mg/m2 85 mg/m2 4 patients (3 evaluable);
0/3 patients with DLT
1 75 mg 800 mg/m2 85 mg/m2 5 patients (3 evaluable);
0/3 patients with DLT
2 100 mg 800 mg/m2 85 mg/m2 3 patients;
0/3 patients with DLT
3 150 mg 800 mg/m2 85 mg/m2 3 patients;
0/3 patients with DLTa
4 150 mg 1000 mg/m2 85 mg/m2 2 patients;
2/2 patients with DLTb
aAdditional 10 patients treated at this dose level in expansion cohort
b Grade 3 diarrhea, grade 4 anemia
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response rate (ORR) was calculated as the relative frequency
of patients who had complete or partial response among all
evaluable patients. Confidence intervals were estimated using




Twenty-eight patients were enrolled between January 2010 and
April 2013 (Table 2), 18 patients were enrolled during the dose
escalation with an additional 10 patients with ABTC, who were
treated at the MTD (Fig. 1). Approximately half of the patients
had intrahepatic cholangiocarcinoma (n = 13), while five patients
had extrahepatic cholangiocarcinoma, eight patients had pancre-
atic cancer, and one patient each had cancer of the gallbladder
and ampulla. All of the patients had a good performance status
(ECOG PS of 1 or better) at time of enrollment. The median age
of the participants was 61.5 years.
Treatment and toxicities
Dose escalation proceeded according to Table 1. At a dose of
150 mg erlotinib with 1000mg/m2 gemcitabine and 85mg/m2
oxaliplatin, two patients experienced a DLT (grade 3 diarrhea
and grade 4 anemia). Therefore, the MTD was determined to
be 150 mg erlotinib given orally on days 3–8 in combination
with gemcitabine 800 mg/m2 and oxaliplatin 85 mg/m2 ad-
ministered on cycle day 1 and 2, respectively.
The most frequent toxicities were nausea (78 %), fatigue
(71 %), neuropathy (68 %), diarrhea (61 %), rash (57 %), and
thrombocytopenia (54%); a majority of these were grade 1–2. A
summary of the significant (≥ grade 3) toxicities is presented in
Table 3, with the most frequent being grade 3 fatigue and gas-
trointestinal toxicities experienced by 3 of 28 and 4 of 28 pa-
tients, respectively. One patient experienced grade 4 cerebral
ischemia that was determined by the investigators to be possibly
related to gemcitabine and erlotinib. As mentioned above, a dose
limiting grade 3 diarrhea and grade 4 anemia were experienced
by two patients. One patient died while on study and was deter-
mined by the investigator to be related to disease progression.
Efficacy
Four patients did not complete one course of therapy (i.e., two
14-day cycles) and thus were not evaluable for efficacy end-
points. Two of the four patients withdrew due to patient or
physician choice, one withdrew due to an unrelated serious
AE, and one patient had disease progression prior to starting
therapy. Of the evaluable patients, disease stabilization (SD)
occurred in 17 patients, 11 of which had ABTC. A complete
response was not observed; however, five patients achieved a
partial response (PR) for an ORR of 21 %. Only one patient
experienced progressive disease (PD) for an observed disease
control rate (DCR) of 92 %. Six patients (25 %) were still on
study at six months and were therefore free from progression
and unacceptable toxicity. The median OS for all patients was
10.6 months (Fig. 2a; 95 % CI, 7.1 to 18.9). In the ABTC
cohort, five of 17 patients achieved a PR for an ORR of 29 %.
Eleven patients (65 %) had SD for a DCR of 94 %. The
Median OS for the ABTC cohort was 18 months (Fig. 2b;
95 % CI, 9.3 to NE (not estimable given the data)).
Correlative studies
Mutational analysis
None of the tumor tissue samples (n = 16) that were evaluated
had detectable deletions in EGFR exon 19 or insertions in EGFR
and HER2 exon 20. Of the 16 tumor tissues sampled for KRAS
alterations, six tissues (38 %) had nonsynonymous KRAS muta-
tions. Two patients with intrahepatic cholangiocarcinoma har-
bored a KRAS mutation in codon 12 (G12A and G12D), and
both of these patients achieved a best response of stable disease.
Three patients with pancreatic cancer that harbored a KRASmu-
tation in codon 12 (G12D) also achieved a best response of stable
disease. Interestingly, an additional pancreatic cancer patient with
a KRASmutation had progressive disease, however the mutation
was in codon 61 (Q61H). In the patients with wildtype KRAS,
two ABTC patients achieved a PR, and four ABTC patients and
Table 2 Patient characteristics
Data Results

















PS Performance status; ECOG Eastern Cooperative Oncology Group
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one pancreatic cancer patient achieved SD. No EGFR hotspot
mutations (L858R, n = 10; L861Q, n = 10; or T790 M, n = 8)
were observed in the samples for which tissue was available.
Immunohistochemistry
All tumor tissues (n = 11) had positive E-cadherin membra-
nous staining with histological score of +1, +2, or +3 with a
majority of the samples (n = 10) demonstrated moderate (+2)
to strong (+3) E-cadherin labeling. Only one patient had pos-
itive vimentin staining (histological score = +2), whereas all
other evaluated samples stained negative (histological
score = 0). No formal statistical associations were evaluated
between E-cadherin or vimentin expression and clinical out-
comes as there were too few tissue samples (n = 8) from
patients where disease response was evaluable.
Discussion
Therapeutic regimens combining chemotherapy with EGFR-
targeted agents are an active area of research. Despite the high
level of EGFR expression in solid tumors, combining EGFR
inhibitors with cytotoxic chemotherapy has not been exception-
ally successful in large-scale clinical trials. For example, in the
TALENT lung cancer trial, erlotinib was added to gemcitabine
and cisplatin without an improvement in OS [25]. Evaluation of
274 patient tumors from the TRIBUTE trial, in which patients
with non-small cell lung cancer were treatedwith carboplatin and
paclitaxel with or without erlotinib, showed a trend towards an
erlotinib benefit on time to progression but not improved survival
[26]. More recently, the BINGO trial in ABTC evaluated
GEMOX with and without cetuximab but did not observe an
improvement in efficacy [27]. Based on the preclinical evidence
suggesting that EGFR tyrosine kinase inhibitors result in a cell
cycle arrest rather than inducing apoptosis [28], it is reasonable to
hypothesize that antagonist effects with a cytotoxic agent such as
chemotherapy may occur. However, based on the preclinical
observation that a pulsatile regimen of EGFR-targeted therapy
in combination with chemotherapy was more effective [15], we
designed the current study to test the hypothesis that erlotinib
administered at periodic time points during standard chemother-
apy would be a synergistic treatment strategy for patients with
ABTC.
The primary objective of this study was to determine the
MTD of GEMOX administered in combination with erlotinib.
32 Assessed for eligibility 
4 Excluded 
3 Not meeting inclusion criteria 
1 Withdrew consent 
28 Treated with Pulsatile Erlotinib 
in Combination with Gemcitabine 
and Oxaliplatin 
18 Dose escalation 
10 Dose expansion 
4 Nonevaluable for response 
24 Evaluable for response 
Samples with mutational analysis 
performed 
16 EGFR exon 19 deletion 
16 EGFR exon 20 insertion 
16 KRAS point mutations 
10 EGFR p.L858R 
10 EGFR p.L861Q 
8 EGFR p.T790M 
6 KRAS point mutations 
4 KRAS p.G12D 
1 KRAS p.G12A 





10 Moderate to strong E-cadherin 
staining 
1 Positive vimentin staining 
Fig. 1 Clinical trial flow diagram
that depicts the number of patients
that were consented, received
study therapy, and evaluable for
response. The diagram also
depicts the number of samples
tested for the correlative analysis,
as well as the correlative results
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TheMTDwas determined (and verified in the dose expansion
cohort) to be 800 mg/m2 GEM, 85 mg/m2 OX, and 150 mg
erlotinib. When the current study was being developed, we
were unaware of the concurrent phase III trial in South
Korea that was investigating continuous erlotinib in combina-
tion with GEMOX compared to GEMOX alone in ABTC
patients [13]. However, despite the slightly different treatment
regimens (phase III study: 100 mg erlotinib administered dai-
ly, 1000 mg/m2 GEM, and 100 mg/m2 OX), the toxicity pro-
files were similar between the two studies suggesting that
erlotinib in combination with chemotherapy is well tolerated
in patients with ABTC.
It is well known that skin rash is a major side effect of
erlotinib, and perhaps pulsatile dosing reduces the incidence
of erlotinib-associated skin rash. A meta-analysis of 2911 pa-
tients with a variety of solid tumors observed that skin rash
associated with single agent erlotinib (150 mg daily) occurred
in 75 % of patients [29]. A phase II study that investigated
daily erlotinib (150 mg) in combination with bevacizumab
(5 mg/kg; Day 1 and 15 of a 28-day cycle) in ABTC reported
that 76 % of patients experienced erlotinib-associated skin
rash [30]. The total incidence of skin rash in our study was
much lower at 57 %, and only 29 % of patients treated at
150 mg developed erlotinib-associated skin rash. Thus, pulsa-
tile dosing (Day 3–8 of a 14-day cycle) of erlotinib could be an
alternative treatment strategy to reduce the incidence of rash.
Although interval dosing of a TKI, such as erlotinib, is attrac-
tive from the context of decreasing the frequency of specific
Table 3 Toxicity ≥3, Any Cycle














Anemia 0 0 0 0 1
Leukopenia 0 1 0 1 0
Neutropenia 1 1 0 1 0
Lymphopenia 0 0 2 0 0
Nonhematologic
Fatigue 0 0 1 2 0
Rash 0 1 0 1 0
Dehydration 0 1 0 0 0
Diarrhea 0 0 0 1 1
Nausea 0 1 0 1 0
Vomiting 0 1 0 0 0
Elevated ALT 0 1 0 1 0
Elevated AST 0 1 0 0 0
Elevated Alk Phos 0 1 0 0 0
Hyperbilirubinemia 0 1 0 0 0
Cerebral Ischemia 0 0 0 1 0
aDetermined to be the recommended phase II dose









95% Confidence Intervals 
Fig. 2 Kaplan-Meier estimates of overall survival stratified by: (A) all
patients (n = 28) on study and (B) only those patients (n = 20) with
advanced biliary tract cancers (excluding pancreas). For all patients on
study, the median overall survival was 10.6 months (95 % confidence
interval, 7.1 to 18.9). The median overall survival in the advanced biliary
tract cohort was 18 months (95 % confidence interval, 9.3 to N/A)
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adverse events, the possibility of the Bdisease flare^ phenom-
enon that occurs after stopping a TKI should not be
overlooked. A retrospective study in non-small cell lung can-
cer investigated the time of development of disease flare after
stopping EGFR TKI (either erlotinib or gefitinib) in patients
that acquired clinical resistance. This study observed a 23 %
flare rate with a median time to disease flare of eight days
(range: 3–21 days) [31]. Thus, this phenomenon should be
considered when designing future treatment regimens that in-
clude interval dosing of erlotinib.
As a secondary objective, we sought to describe any anti-
tumor activity associated with the combination of pulsatile
erlotinib and GEMOX. As this study completed enrollment,
the phase III trial of daily erlotinib plus GEMOXwas present-
ed. The South Korean study demonstrated a non-significant
improvement in progression-free survival in the cohort treated
with erlotinib plus GEMOX compared to GEMOX alone [13].
This lack of significance could be in part a result of erlotinib
inducing G1/S cell cycle arrest, instead of apoptosis, which
theoretically blocks the subsequent effects of cytotoxic che-
motherapy [28]. We observed an ORR of 29 % in the ABTC
cohort, which is similar to the 30 % ORR observed by Lee
et al. [13]. However, the combination chemotherapy plus pul-
satile erlotinib tested in the current study achieved a 94 %
DCR compared to 66 % in the phase III study. Furthermore,
we observed a provocative OS of 18 months in our ABTC
cohort. While these two studies differed in treatment
doses, patient demographics, and number of allowed
prior therapies, our data suggest that a therapeutic reg-
imen combining chemotherapy with pulsatile dosing of
erlotinib may be a better treatment strategy. However,
due to the nature of our study design (i.e., phase Ib, 3 + 3
dose-escalation with expansion at the MTD), caution should
be taken when interpreting the observed clinical activity due
to the small number of patients evaluated in this study. Further
prospective trials with larger sample sizes would be needed to
confirm activity.
The choice of chemotherapy (e.g., GEMOX) for this study
was based on preclinical clinical data showing synergy and
clinical efficacy observed in ABTC [4, 32, 33]. Subsequent to
the development of our study, gemcitabine plus cisplatin rath-
er than oxaliplatin has emerged as the chemotherapy standard
in ABTC. The phase III ABC-02 trial observed an improve-
ment in both ORR (26 % versus 15%) and DCR (81 % versus
72 %) with gemcitabine plus cisplatin compared to single
agent gemcitabine with an excellent toxicity profile [6].
Therefore, one might hypothesize that investigating pulsatile
dosing of erlotinib with gemcitabine and cisplatin could be
more beneficial. However, the lack of a survival advantage
seen by adding erlotinib in the Phase III study with
GEMOX limits enthusiasm for exploring this combination
with an alternate chemotherapy backbone at the current time.
Ideally, as understanding of the complex landscape of the
heterogeneous biology of ABTC improves, this could be a
future direction, but likely only in a subset of patients.
We had hoped to find a molecularly defined subset of bil-
iary cancers from this study that would be particularly sensi-
tive to EGFR inhibition. Activating mutations in EGFR are
well-described predictors of response to erlotinib in lung can-
cer [34–37]. We found no EGFR mutations in our patients
while the South Korean group found two patients with exon
20 mutations out of 116 total (1.6 %). Although KRAS muta-
tional status is an established negative predictor of response to
anti-EGFR therapies in colorectal cancer [38, 39], it is current-
ly unknown if this status predicts response in patients with
ABTC. The South Korean phase III study suggested a survival
benefit with the addition of erlotinib to GEMOX in patients
with wild-type KRAS [19]. Of the 11 ABTC patients in our
study that had available tissue for KRAS testing, two with
wild-type KRAS achieved a partial response, whereas the
two ABTC patients with a KRAS mutation had stable disease.
Thus, our results are in concordance with the previous phase
III study suggesting a trend towards a survival advantage
when chemotherapy is combined with anti-EGFR therapy in
ABTC patients with wild-type KRAS. However, contradictory
to the observed trends in survival for wild-typeKRAS patients,
three of the six patients with a KRAS mutation in the South
Korean phase III study still responded to the combination
therapy [19]. Furthermore, Gruenberger et al. investigated
GEMOX in combination with cetuximab and reported that
two of the three patients with KRAS mutations achieved a
partial response [12]. These contradictory findings between
KRAS mutation and response suggest that anti-EGFR thera-
pies or, more likely, GEMOX might be beneficial irrespective
of KRASmutation in ABTC; however, further investigation is
still needed to fully characterize the prognostic indication of a
KRASmutation in advanced biliary cancers. The TCGA anal-
ysis of biliary cancers demonstrates that there is extensive
molecular heterogeneity of these tumors [40]. At the present
time it is unclear what role, if any, EGFR inhibitors such as
erlotinib may have in emerging subsets such as FGFRmutant,
IDH mutant or microsatellite instability high tumors where
more specific targeted or immunotherapy has demonstrated
response [41–43].
In conclusion, pulsatile erlotinib with GEMOX adminis-
tered at the established MTD was well tolerated with an ac-
ceptable toxicity profile in patients with advanced pancreatic
and biliary tract cancers. Additionally, this treatment combi-
nation resulted in encouraging anti-tumor activity as evi-
denced by a high disease control rate and longer median OS
in an ABTC cohort.
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